Aquestive Therapeutics (NASDAQ:AQST) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Aquestive Therapeutics (NASDAQ:AQST) from a hold rating to a sell rating in a research note issued to investors on Saturday.

A number of other analysts have also weighed in on AQST. Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Friday, July 17th. Oppenheimer started coverage on shares of Aquestive Therapeutics in a report on Friday, April 24th. They set an “outperform” rating and a $8.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Aquestive Therapeutics presently has an average rating of “Buy” and a consensus target price of $8.50.

Aquestive Therapeutics Price Performance

AQST stock opened at $4.29 on Friday. The business has a fifty day moving average price of $4.15 and a 200 day moving average price of $4.09. Aquestive Therapeutics has a fifty-two week low of $2.93 and a fifty-two week high of $7.55. The stock has a market capitalization of $538.45 million, a price-to-earnings ratio of -6.60 and a beta of 1.49.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.08). The business had revenue of $13.82 million during the quarter, compared to analysts’ expectations of $11.42 million. On average, equities analysts expect that Aquestive Therapeutics will post -0.45 earnings per share for the current fiscal year.

Insider Transactions at Aquestive Therapeutics

In other Aquestive Therapeutics news, Director Julie Krop sold 25,000 shares of the company’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $5.02, for a total transaction of $125,500.00. Following the transaction, the director owned 25,000 shares of the company’s stock, valued at approximately $125,500. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.81% of the company’s stock.

Institutional Investors Weigh In On Aquestive Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. NewEdge Advisors LLC bought a new stake in shares of Aquestive Therapeutics during the third quarter worth $28,000. BNP Paribas Financial Markets boosted its holdings in Aquestive Therapeutics by 78.3% in the second quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock valued at $31,000 after acquiring an additional 4,134 shares during the last quarter. Modern Wealth Management LLC acquired a new stake in Aquestive Therapeutics in the second quarter worth about $33,000. Elevation Point Wealth Partners LLC acquired a new stake in Aquestive Therapeutics in the first quarter worth about $42,000. Finally, ADAR1 Capital Management LLC raised its holdings in Aquestive Therapeutics by 103.9% during the 1st quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company’s stock worth $42,000 after purchasing an additional 264,000 shares during the last quarter. 32.45% of the stock is owned by institutional investors and hedge funds.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.